Patient-reported outcomes (PRO) from a 104 week, phase 3, randomised, placebo-controlled study comparing once weekly dulaglutide to sitagliptin and placebo in metformin-treated patients with Type 2 diabetes; the Assessment of Weekly Administration of Dulaglutide in Diabetes (AWARD-5) trial

被引：0

作者：

Reaney, M. ^{[1
]}

Yu, M. ^{[2
]}

Adetunji, O. ^{[3
]}

Milicevic, Z. ^{[4
]}

机构：

[1] Eli Lilly & Co, Global Hlth Outcomes, Windlesham, Surrey, England

[2] Eli Lilly & Co, Global Stat Sci, Toronto, ON, Canada

[3] Eli Lilly & Co, Dept Med, Basingstoke, Hants, England

[4] Eli Lilly & Co, Dept Med, Vienna, Austria

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：50 / 50

页数：1